MetaVia Inc. (NASDAQ:MTVA) stock is surging on Friday, up by 35%, roaring back after a brief pause in its massive weekly rally.

The stock is reversing a downward profit-taking trend observed during Thursday's trading session.

The Nasdaq is up 0.49% while the S&P 500 has gained 0.46%.

Peer-Reviewed Research Drives Rebound

The Friday surge stems from the publication of new peer-reviewed research confirming the efficacy of MetaVia's drug vanoglipel (DA-1241).

On Wednesday, the Cambridge, Massachusetts-based company published preclinical data in the journal Biomolecules & Therapeutics.

The study, titled "A Novel Anti-Fibrotic Role of G-Protein-Coupled Receptor 119 in Hepatic Stellate Cells," demonstrated that GPR119 agonists reduce liver fibrosis.

CEO Confirms Phase 2a Consistency

The newly published findings independently validate MetaVia's clinical pipeline. In the announcement, Hyung Heon Kim, President and CEO of MetaVia, stated, "In the trial, patients treated with vanoglipel demonstrated statistically significant reductions in ALT levels, and the serum fibrosis marker TIMP1, along with a positive trend in liver fibrosis as measured by VCTE (-10.2% from the baseline vs. +10.1% for placebo) after 16-week treatment."

Clinical Pipeline Targets MASH

MetaVia continues to focus its clinical-stage biotechnology pipeline on cardiometabolic diseases. Beyond testing vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis (MASH), the company is actively developing DA-1726, a dual agonist targeting obesity.

Critical Technical Levels for MetaVia (MTVA) Stock

MTVA is now trading well above its short- and intermediate-term trend gauges, sitting 144.4% above the 20-day SMA ($1.51) and 155.7% above the 50-day SMA ($1.44), which signals aggressive upside momentum. It's also 49.6% above the 100-day SMA ($2.46), but still 36.9% below the 200-day SMA ($5.83).

RSI is the cleanest momentum read right now: at 79.77, it's in overbought territory.

The moving-average structure is mixed: the 20-day SMA is above the 50-day SMA (bullish near-term), but the stock is still living under the death cross that formed in November 2025 (50-day below 200-day).

  • Key Resistance: $5.83
  • Key Support: $2.46

MTVA Price Action: MetaVia shares were up 35.20% at $3.88 at the time of publication on Friday, according to Benzinga Pro data.

Photo by MMD Creative via Shutterstock